GOLDSTONE ASIA PHARM(300434.SZ)

Company Encyclopedia
View More
name
GOLDSTONE ASIA PHARM
300434.SZ
Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, and sale of medicines and health products in China. The company offers over-the-counter drugs, prescription drugs, raw materials and health foods. It produces and sells plastic composite pipes, pipe fittings and equipment, as well as develops vacuum coating, industrial machinery, pipe fitting molds, construction equipment, and special equipment.
3.027 T
300434.SZMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking155/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.29%C
    • Profit Margin12.37%B
    • Gross Margin57.36%B
  • Growth ScoreC
    • Revenue YoY-7.43%D
    • Net Profit YoY186.30%A
    • Total Assets YoY6.70%B
    • Net Assets YoY4.24%C
  • Cash ScoreC
    • Cash Flow Margin808.41%B
    • OCF YoY-7.43%D
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreA
    • Gearing Ratio16.02%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GOLDSTONE ASIA PHARM: Diclofenac Sodium Sustained-Release Tablets Pass Consistency Evaluation

    GOLDSTONE ASIA PHARM's wholly-owned subsidiary, Zhejiang Di'er Pharmaceutical, recently received approval from the National Medical Products Administration for the sodium diclofenac sustained-release tablets (0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs. This medication is suitable for alleviating acute episodes of chronic arthritis such as rheumatoid arthritis and osteoarthritis, as well as various soft tissue rheumatic pains

    Zhitong·
    SZ
    300434
    -0.39%
    Zhitong·
    SZ
    300434
    -0.39%

    GOLDSTONE ASIA PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 96.7659 million yuan, an increase of 66.47%

    GOLDSTONE ASIA PHARM released its third-quarter report for 2025, with operating revenue of 707.8 million yuan in the first three quarters, a year-on-year decrease of 6.37%. The net profit attributable to the parent company was 96.7659 million yuan, a year-on-year increase of 66.47%; the net profit excluding non-recurring gains and losses was 79.0115 million yuan, a year-on-year increase of 51.82%. The basic earnings per share were 0.24 yuan

    Zhitong·
    SZ
    300434
    -0.39%
    Zhitong·
    SZ
    300434
    -0.39%

    GOLDSTONE ASIA PHARM issued a profit forecast, expecting a net profit of RMB 86.6055 million to RMB 107 million in the first three quarters, a year-on-year increase of 48.99% to 83.95%

    GOLDSTONE ASIA PHARM expects its net profit for the first three quarters of 2025 to be between 86.6055 million yuan and 107 million yuan, a year-on-year increase of 48.99% to 83.95%. The net profit after deducting non-recurring gains and losses is expected to be between 69.1279 million yuan and 89.4488 million yuan, a year-on-year increase of 32.83% to 71.88%. The company has achieved a year-on-year decrease in period expenses through budget optimization and cost control measures, with overall business developing steadily, and both revenue and gross profit in the new materials and machinery business segments showing year-on-year improvement

    Zhitong·
    SZ
    300434
    -0.39%
    Zhitong·
    SZ
    300434
    -0.39%

    GOLDSTONE ASIA PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 65.7454 million yuan, an increase of 67.71%

    GOLDSTONE ASIA PHARM released its semi-annual report for 2025, with operating revenue of 492 million yuan, a year-on-year decrease of 5.80%. The net profit attributable to the parent company was 65.7454 million yuan, a year-on-year increase of 67.71%; the net profit excluding non-recurring gains and losses was 55.723 million yuan, a year-on-year increase of 50.45%. The basic earnings per share were 0.1637 yuan

    Zhitong·
    SZ
    300434
    -0.39%
    Zhitong·
    SZ
    300434
    -0.39%

    GOLDSTONE ASIA PHARM: Expected net profit in the first half of the year to grow by 50.04%-85.24% year-on-year

    GOLDSTONE ASIA PHARM announced that it expects a net profit of RMB 58.8172 million to RMB 72.6178 million in the first half of 2025, an increase of 50.04% to 85.24% compared to RMB 39.2022 million in the same period last year

    Zhitong·
    SZ
    300434
    -0.39%
    Zhitong·
    SZ
    300434
    -0.39%
    © 2026 Longbridge｜Disclaimer